BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22493298)

  • 1. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining.
    Chakraborty S; Stark JM; Sun CL; Modi H; Chen W; O'Connor TR; Forman SJ; Bhatia S; Bhatia R
    Blood; 2012 Jun; 119(26):6187-97. PubMed ID: 22493298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR/ABL and chromosomal instability: debate resolved.
    Carroll M
    Blood; 2012 Jun; 119(26):6180-1. PubMed ID: 22745295
    [No Abstract]   [Full Text] [Related]  

  • 3. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.
    Valeri A; Alonso-Ferrero ME; Río P; Pujol MR; Casado JA; Pérez L; Jacome A; Agirre X; Calasanz MJ; Hanenberg H; Surrallés J; Prosper F; Albella B; Bueren JA
    PLoS One; 2010 Dec; 5(12):e15525. PubMed ID: 21203397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Exp Hematol; 1999 Sep; 27(9):1384-96. PubMed ID: 10480429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
    Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
    Chu S; McDonald T; Bhatia R
    Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
    Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
    Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
    Spencer A; Granter N
    Exp Hematol; 1999 Sep; 27(9):1397-401. PubMed ID: 10480430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR/ABL stimulates WRN to promote survival and genomic instability.
    Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
    Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment.
    Clarkson B; Strife A
    Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.